List view / Grid view
15 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...
15 August 2013 | By Novartis
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)...
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."
14 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim grew further in the first half of 2013, despite difficult overall conditions...
Pharmaceutical manufacturers and regulatory agencies can now enhance the performance of the Thermo Scientific TruScan RM analyzer by downloading the newest software update. In addition to improved speed, Thermo Fisher Scientific designed the software update to enable users to more effectively develop and validate robust methods for pharmaceutical manufacturing and…
12 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA and Perrigo Company announced the launch of the generic equivalent to Temodar® (temozolomide)...
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
12 August 2013 | By Amgen
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement...
11 August 2013 | By METTLER TOLEDO
On the 3rd June, 2013, USP published the revised mandatory Chapter 41 on balances as well as new updates to the advisory Chapter 1251.
10 August 2013 | By TSI Inc.
The BIOTRAK Particle Counter is a full-featured instrument that detects the total number of particles in the air as well as determines which of those particles are viable in nature...
8 August 2013 | By Novo Nordisk
Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir®...
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
8 August 2013 | By Johnson & Johnson
Janssen announced that the European Commission has approved the use of VELCADE® (bortezomib)...
8 August 2013 | By Novartis
"At Novartis, we believe that everyone should have access to early screening programs and innovative therapies..."
8 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the launch of Action Potential Venture Capital (APVC) Limited...
